Evommune, Inc.
EVMN
$14.65
$0.584.12%
NYSE
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 152.77% | 80.79% | 157.05% | 14.28% | 7.88% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 51.76% | 32.84% | 38.51% | 41.24% | -18.72% |
| Operating Income | -51.76% | -59.35% | -38.51% | 19.31% | 18.72% |
| Income Before Tax | -137.71% | -48.89% | -36.41% | 21.62% | 50.46% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -137.71% | -48.89% | -36.41% | 21.62% | 50.46% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -137.71% | -48.89% | -36.41% | 21.62% | 50.46% |
| EBIT | -51.76% | -59.35% | -38.51% | 19.31% | 18.72% |
| EBITDA | -51.83% | -61.07% | -39.33% | 19.58% | 19.11% |
| EPS Basic | 89.86% | 93.21% | 90.17% | 22.85% | 51.33% |
| Normalized Basic EPS | 89.87% | 93.21% | 89.46% | 22.85% | 51.33% |
| EPS Diluted | 89.86% | 93.21% | 90.17% | 22.85% | 51.33% |
| Normalized Diluted EPS | 89.87% | 93.21% | 89.46% | 22.85% | 51.33% |
| Average Basic Shares Outstanding | 2,245.40% | 2,093.49% | 1,194.06% | 1.59% | 1.78% |
| Average Diluted Shares Outstanding | 2,245.40% | 2,093.49% | 1,194.06% | 1.59% | 1.78% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |